来卡尼地平/依那普利联合治疗肥胖相关性高血压

IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE
Integrated Blood Pressure Control Pub Date : 2016-04-26 eCollection Date: 2016-01-01 DOI:10.2147/IBPC.S92779
Guido Grassi
{"title":"来卡尼地平/依那普利联合治疗肥胖相关性高血压","authors":"Guido Grassi","doi":"10.2147/IBPC.S92779","DOIUrl":null,"url":null,"abstract":"<p><p>Obesity-related hypertension represents a condition frequently observed in current clinical practice characterized by a complex pathophysiological background and a very high cardiovascular risk profile, particularly in severely obese individuals. This explains, on the one hand, the difficulty in reducing elevated blood pressure values in this pathological state and, on the other, the need to achieve this goal in a relatively short-time period to prevent the occurrence of fatal and nonfatal cardiovascular events. Both nonpharmacological and pharmacological measures are available in the therapeutic approach for this condition. Among the pharmacological interventions, a combination of two antihypertensive drugs represents the most common recommended strategy aimed at achieving blood pressure control. This paper, after briefly examining the main pathophysiological features of obesity-related hypertension, will review the importance in the treatment of this condition of the drug combination based on a calcium channel blocker and an angiotensin-converting enzyme inhibitor, with specific focus on lercanidipine/enalapril. Following an analysis of the main pharmacological properties of the combination, the results of the studies based on this pharmacological approach in obesity-related hypertension will be critically discussed. The efficacy, safety, and tolerability profile of the lercanidine/enalapril drug combination as well as its potential limitations will also be examined. </p>","PeriodicalId":45299,"journal":{"name":"Integrated Blood Pressure Control","volume":"9 ","pages":"69-77"},"PeriodicalIF":1.5000,"publicationDate":"2016-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/IBPC.S92779","citationCount":"2","resultStr":"{\"title\":\"Lercanidipine/enalapril combination in the management of obesity-related hypertension.\",\"authors\":\"Guido Grassi\",\"doi\":\"10.2147/IBPC.S92779\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Obesity-related hypertension represents a condition frequently observed in current clinical practice characterized by a complex pathophysiological background and a very high cardiovascular risk profile, particularly in severely obese individuals. This explains, on the one hand, the difficulty in reducing elevated blood pressure values in this pathological state and, on the other, the need to achieve this goal in a relatively short-time period to prevent the occurrence of fatal and nonfatal cardiovascular events. Both nonpharmacological and pharmacological measures are available in the therapeutic approach for this condition. Among the pharmacological interventions, a combination of two antihypertensive drugs represents the most common recommended strategy aimed at achieving blood pressure control. This paper, after briefly examining the main pathophysiological features of obesity-related hypertension, will review the importance in the treatment of this condition of the drug combination based on a calcium channel blocker and an angiotensin-converting enzyme inhibitor, with specific focus on lercanidipine/enalapril. Following an analysis of the main pharmacological properties of the combination, the results of the studies based on this pharmacological approach in obesity-related hypertension will be critically discussed. The efficacy, safety, and tolerability profile of the lercanidine/enalapril drug combination as well as its potential limitations will also be examined. </p>\",\"PeriodicalId\":45299,\"journal\":{\"name\":\"Integrated Blood Pressure Control\",\"volume\":\"9 \",\"pages\":\"69-77\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2016-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/IBPC.S92779\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Integrated Blood Pressure Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/IBPC.S92779\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrated Blood Pressure Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/IBPC.S92779","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 2

摘要

肥胖相关性高血压是当前临床实践中经常观察到的一种疾病,其特点是具有复杂的病理生理背景和非常高的心血管风险,特别是在严重肥胖个体中。这一方面解释了在这种病理状态下降低血压升高值的困难,另一方面,需要在相对较短的时间内实现这一目标,以防止致命和非致命心血管事件的发生。在治疗方法中,非药物和药物措施都是可用的。在药理学干预措施中,两种降压药物的联合使用是最常见的推荐策略,旨在实现血压控制。本文在简要介绍肥胖相关性高血压的主要病理生理特征后,将回顾以钙通道阻滞剂和血管紧张素转换酶抑制剂为基础的药物联合治疗肥胖相关性高血压的重要性,特别关注莱卡尼地平/依那普利。在分析了联合用药的主要药理学特性后,将对基于这种药理学方法的肥胖相关性高血压研究结果进行批判性讨论。此外,还将对莱卡尼定/依那普利联合用药的有效性、安全性和耐受性以及潜在的局限性进行研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lercanidipine/enalapril combination in the management of obesity-related hypertension.

Obesity-related hypertension represents a condition frequently observed in current clinical practice characterized by a complex pathophysiological background and a very high cardiovascular risk profile, particularly in severely obese individuals. This explains, on the one hand, the difficulty in reducing elevated blood pressure values in this pathological state and, on the other, the need to achieve this goal in a relatively short-time period to prevent the occurrence of fatal and nonfatal cardiovascular events. Both nonpharmacological and pharmacological measures are available in the therapeutic approach for this condition. Among the pharmacological interventions, a combination of two antihypertensive drugs represents the most common recommended strategy aimed at achieving blood pressure control. This paper, after briefly examining the main pathophysiological features of obesity-related hypertension, will review the importance in the treatment of this condition of the drug combination based on a calcium channel blocker and an angiotensin-converting enzyme inhibitor, with specific focus on lercanidipine/enalapril. Following an analysis of the main pharmacological properties of the combination, the results of the studies based on this pharmacological approach in obesity-related hypertension will be critically discussed. The efficacy, safety, and tolerability profile of the lercanidine/enalapril drug combination as well as its potential limitations will also be examined.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Integrated Blood Pressure Control
Integrated Blood Pressure Control PERIPHERAL VASCULAR DISEASE-
CiteScore
4.60
自引率
0.00%
发文量
13
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信